fbpx

Proteins protect against cataracts

 

Researchers from Germany recently discovered the activation mechanism of one of the proteins that protect the eye against cataracts, laying the foundation for the development of new therapies.

 

The refractive power of the human eye depends on a highly concentrated protein solution. Two proteins in particular, ɑA-cristallin and ɑB-cristallin, ensure that other proteins do not turn into clumps over time. When this protective mechanism fails, the patient develops a cataract. 

 

“The great challenge in the analysis of these two crystallin types lies in their inordinate variety,” explains Johannes Buchner, professor for biotechnology at the Technical University of Munich. “These proteins exist as a mixture of very different forms, each comprising a variable number of subunits. This makes it very difficult to distinguish the individual structures from one to the other.”

 

In 2009, the German team had deciphered part of ɑB-cristallin, a molecule comprising 24 subunits, but found that in its idle form, it contributes little to the protection of the eye. It needed a trigger mechanism to activate it. This mechanism has now been uncovered.

 

These new insights provide a solid foundation for developing new therapeutic approaches. For instance, medication to treat cataracts could activate ɑB-cristallin, which would be in charge of clearing up cloudy lenses. This could eventually replace the need for surgery.

Source:

http://www.sciencedaily.com/releases/2013/10/131023141130.htm

Featured Posts

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read More
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read More
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read More
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read More

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more